Robert C F Leonard
Overview
Explore the profile of Robert C F Leonard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
278
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lambertini M, Moore H, Leonard R, Loibl S, Munster P, Bruzzone M, et al.
J Clin Oncol
. 2018 May;
36(19):1981-1990.
PMID: 29718793
Purpose The role of temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal women remains controversial. This systematic...
2.
Mansi J, Yellowlees A, Lipscombe J, Earl H, Cameron D, Coleman R, et al.
Breast Cancer Res Treat
. 2010 Jun;
122(3):787-94.
PMID: 20559708
To compare the long-term outcome of women with primary or locally advanced breast cancer randomised to receive either doxorubicin and cyclophosphamide (AC) or doxorubicin and docetaxel (AD) as primary chemotherapy....
3.
Morgan C, Lewis P, Jones R, Bertelli G, Thomas G, Leonard R
Acta Oncol
. 2007 Jun;
46(5):669-77.
PMID: 17562444
Bisphosphonates and chemotherapy have increasingly gained favour in the treatment of metastatic hormone resistant prostate cancer. We investigated whether zoledronic acid, at a concentration found at the bone, would enhance...
4.
Poole C, Earl H, Hiller L, Dunn J, Bathers S, Grieve R, et al.
N Engl J Med
. 2006 Nov;
355(18):1851-62.
PMID: 17079759
Background: The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial examined the efficacy of anthracyclines in the adjuvant treatment of early breast cancer. Methods: In NEAT, we compared four...
5.
Bertelli G, Garrone O, Merlano M, Occelli M, Bertolotti L, Castiglione F, et al.
Oncology
. 2006 Jan;
69(6):471-7.
PMID: 16410685
Background: The steroidal aromatase inactivator exemestane has demonstrated activity after prior failure of non-steroidal aromatase inhibitors (including third-generation inhibitors letrozole and anastrozole) in postmenopausal women with advanced breast cancer. If...
6.
Bertelli G, Garrone O, Bertolotti L, Occelli M, Conforti S, Marzano N, et al.
Oncology
. 2005 Jul;
68(4-6):364-70.
PMID: 16020964
Objectives: Maintenance hormone therapy after first-line chemotherapy is routinely used by many clinicians in advanced breast cancer patients with potentially hormone-sensitive tumors, although there are insufficient evidences in the literature...
7.
Evans T, Yellowlees A, Foster E, Earl H, Cameron D, Hutcheon A, et al.
J Clin Oncol
. 2005 Apr;
23(13):2988-95.
PMID: 15860854
PURPOSE To compare the clinical and pathologic response rates of doxorubicin and cyclophosphamide (AC) with doxorubicin and docetaxel (AD) as primary chemotherapy in women with primary or locally advanced breast...
8.
Leonard R, Lind M, Twelves C, Coleman R, Van Belle S, Wilson C, et al.
J Natl Cancer Inst
. 2004 Jul;
96(14):1076-83.
PMID: 15265969
Background: Breast cancer patients with four or more positive axillary lymph nodes who are treated with conventional adjuvant therapy have a poor prognosis. In uncontrolled studies, high-dose chemotherapy produced much...